Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28344139 | 0.80 | NPSR1 (0.55) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL9504950 | 0.79 | NPSR1 (0.53) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL9502744 | 0.79 | NPSR1 (0.53) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL12145773 | 0.78 | NPSR1 (0.55) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL10722861 | 0.76 | NPSR1 (0.50) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL7087262 | 0.76 | MAPT (0.47) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL11835605 | 0.76 | NPSR1 (0.50) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL7321877 | 0.76 | PARP1 (0.61) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL3287768 | 0.75 | ALDH1A1 (0.52) | MAPTGAAPOLBMEN1KMT2A | |
| SCHEMBL6957142 | 0.75 | NPSR1 (0.49) | MEN1KMT2AL3MBTL1NPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| CN-102171875-A | Fuel cell, electronic device and buffer solution for fuel cell | SONY CORP | 2011-08-31 | — | — | CN | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20060106262-A1 | Electrooptic chromophores with large optical birefringence for applications at high speed and short wavelengths | OPTIMER PHOTONICS, INC. | 2006-05-18 | — | — | US | disclosed |
| EP-1185265-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1185265-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6300325-B1 | HETEROCYCLIC RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION | 2001-10-09 | — | — | US | disclosed |
| WO-2000076501-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0991406-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-0991406-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998032439-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106262-A1 | Electrooptic chromophores with large optical birefringence for applications at high speed and short wavelengths | EYA2, CRY2, EYA3 | MAPT 2075/4885GAA 2647/4885POLB 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.